First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 13
页数：2
相关论文
共 50 条
  • [41] IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
    Huang, Chengliang
    Gan, Gregory N.
    Zhang, Jun
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [42] Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China
    Xiang, Guiyuan
    Jiang, Tingting
    Gan, Lanlan
    Wu, Yuanlin
    Zhang, Ni
    Xing, Haiyan
    Su, Hui
    Li, Yanping
    Peng, Dan
    Ni, Rui
    Liu, Yao
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [43] Efficacy analysis and prognostic factors of first-line chemotherapy combined with immunotherapy in extensive-stage small cell lung cancer: a real-world study
    Jian-Xi Zhou
    Yun-Chuan Sun
    Li Xiao
    Hong-Ling Lu
    Xiao-Ming Yin
    Kui Fan
    Ying-Nan Zhou
    Scientific Reports, 15 (1)
  • [44] Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
    Gao, F.
    Zhao, Y.
    Li, X.
    Li, Y.
    Ma, T.
    Li, Q.
    Tang, X.
    Han, X.
    Yi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1069 - S1069
  • [45] IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
    Chengliang Huang
    Gregory N. Gan
    Jun Zhang
    Journal of Hematology & Oncology, 13
  • [46] Chemoimmunotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer and ECOG Performance Status of 2 or 3
    Agarwal, M.
    Liu, A.
    Langlais, B.
    Leventakos, K.
    Yu, N. Y.
    Almquist, D.
    Manochakian, R.
    Ernani, V.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S543 - S543
  • [47] Clinicopathological Features and First-Line Treatment Outcomes of Geriatric Patients With Extensive-Stage Small Cell Lung Cancer: A Multicenter Study
    Ilhan, Aysegul
    Gurler, Fatih
    Yilmaz, Funda
    Seyran, Erdogan
    Bastug, Vural
    Gorgulu, Bugra
    Eraslan, Emrah
    Yildirim, Ozgen Ahmet
    Yazici, Ozan
    Oksuzoglu, Omur Berna Cakmak
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (03)
  • [48] Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
    Zhao, Y.
    Liu, J.
    Li, X.
    Li, Y.
    Pu, H.
    Wang, X.
    Yang, M.
    Bai, S.
    Guo, L.
    Zhao, L.
    Zhang, M.
    Zhao, H.
    Xu, S.
    Wang, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1674 - S1674
  • [49] A multicenter phase I/II trial of induction chemotherapy followed by camrelizumab, apatinib, plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer
    Zhou, Chengzhi
    Liu, Ming
    Qiu, Guihuan
    Xie, Xiaohong
    Lin, Xinqing
    Guan, Wenhui
    Xie, Zhanhong
    Zhang, Jiexia
    Qin, Yinyin
    Du, Haijian
    Chen, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Is prophylactic cranial irradiation (PCI) needed in patients with extensive-stage small cell lung cancer showing complete response to first-line chemotherapy?
    Nosaki, Kaname
    Seto, Takashi
    Shimokawa, Mototsugu
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 (03) : 344 - 348
12345